In recent months, Intuitive Surgical has faced FDA Class I recalls on certain da Vinci stapler components and visible institutional selling, reflecting elevated concern around product safety and regulatory scrutiny despite earlier strong quarterly results. These developments coincide with ongoing competition in surgical robotics and highlight how regulatory risk and large investor behavior can quickly influence perceptions of an otherwise growing, cash-generative business model. We’ll now...